203 related articles for article (PubMed ID: 10901963)
1. Strontium and samarium therapy for bone metastases from prostate carcinoma.
Dickie GJ; Macfarlane D
Australas Radiol; 1999 Nov; 43(4):476-9. PubMed ID: 10901963
[TBL] [Abstract][Full Text] [Related]
2. Systemic administration of new therapeutic radioisotopes, including phosphorus, strontium, samarium, and rhenium.
Porter AT; Ben-Josef E; Davis L
Curr Opin Oncol; 1994 Nov; 6(6):607-10. PubMed ID: 7827173
[TBL] [Abstract][Full Text] [Related]
3. [Radionuclide therapy for painful bone metastases].
Szefer J; Zuchora Z
Wiad Lek; 2004; 57(5-6):280-3. PubMed ID: 15518077
[TBL] [Abstract][Full Text] [Related]
4. Radiopharmaceuticals for the palliation of painful bone metastasis-a systemic review.
Bauman G; Charette M; Reid R; Sathya J
Radiother Oncol; 2005 Jun; 75(3):258-70. PubMed ID: 16299924
[TBL] [Abstract][Full Text] [Related]
5. Systemic radionuclide therapy of bone metastases with strontium-89.
Porter AT; Davis LP
Oncology (Williston Park); 1994 Feb; 8(2):93-6; discussion 96, 99-101. PubMed ID: 8167090
[TBL] [Abstract][Full Text] [Related]
6. Strontium 89 therapy for the palliation of pain due to osseous metastases.
Robinson RG; Preston DF; Schiefelbein M; Baxter KG
JAMA; 1995 Aug; 274(5):420-4. PubMed ID: 7542352
[TBL] [Abstract][Full Text] [Related]
7. [Metabolic radiotherapy: what role will it have in 2001?].
George B; Douard MC; Rain JD
Cancer Radiother; 2002 May; 6(3):188-200. PubMed ID: 12116845
[TBL] [Abstract][Full Text] [Related]
8. Radionuclides for metastatic bone pain palliation: a need for rational re-evaluation in the new millennium.
Krishnamurthy GT; Krishnamurthy S
J Nucl Med; 2000 Apr; 41(4):688-91. PubMed ID: 10768570
[No Abstract] [Full Text] [Related]
9. EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides.
Handkiewicz-Junak D; Poeppel TD; Bodei L; Aktolun C; Ezziddin S; Giammarile F; Delgado-Bolton RC; Gabriel M
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):846-859. PubMed ID: 29453701
[TBL] [Abstract][Full Text] [Related]
10. Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement.
Kraeber-Bodéré F; Campion L; Rousseau C; Bourdin S; Chatal JF; Resche I
Eur J Nucl Med; 2000 Oct; 27(10):1487-93. PubMed ID: 11083537
[TBL] [Abstract][Full Text] [Related]
11. ESR dosimetry of 89Sr and 153Sm in bone.
Kinoshita A; Braga FJ; Graeff CF; Baffa O
Appl Radiat Isot; 2001 Feb; 54(2):269-74. PubMed ID: 11200888
[TBL] [Abstract][Full Text] [Related]
12. Strontium-89 chloride (Metastron) for palliative treatment of bony metastases. The University of Minnesota experience.
Lee CK; Aeppli DM; Unger J; Boudreau RJ; Levitt SH
Am J Clin Oncol; 1996 Apr; 19(2):102-7. PubMed ID: 8610630
[TBL] [Abstract][Full Text] [Related]
13. Decreased serum E-selectin concentration after 89Sr-chloride therapy for metastatic prostate cancer bone pain.
Papatheofanis FJ
J Nucl Med; 2000 Jun; 41(6):1021-4. PubMed ID: 10855628
[TBL] [Abstract][Full Text] [Related]
14. New research developments increase therapeutic options for thyroid cancer and bone pain palliation.
Williams JE
J Nucl Med; 1997 Nov; 38(11):19N-20N, 26N. PubMed ID: 9374327
[No Abstract] [Full Text] [Related]
15. [89Sr Therapy for pain relief in patients with bone metastases].
Koizumi K; Arbab AS; Toyama K; Shirasu M; Osawa S; Araki T; Yamaguchi M; Onishi H; Araki T; Arai T; Komatsu H; Ueno A; Nokata H
Kaku Igaku; 1996 Nov; 33(11):1243-8. PubMed ID: 8986064
[TBL] [Abstract][Full Text] [Related]
16. Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer.
Pons F; Herranz R; Garcia A; Vidal-Sicart S; Conill C; Grau JJ; Alcover J; Fuster D; Setoain J
Eur J Nucl Med; 1997 Oct; 24(10):1210-4. PubMed ID: 9323260
[TBL] [Abstract][Full Text] [Related]
17. Strontium-89 (Metastron) in the treatment of prostate cancer metastatic to bone.
Porter AT
Eur Urol; 1994; 26 Suppl 1():20-5. PubMed ID: 7537665
[TBL] [Abstract][Full Text] [Related]
18. Targeted radionuclide therapy for bone metastases.
Lewington VJ
Eur J Nucl Med; 1993 Jan; 20(1):66-74. PubMed ID: 7678397
[TBL] [Abstract][Full Text] [Related]
19. Quantitation of biochemical markers of bone resorption following strontium-89-chloride therapy for metastatic prostatic carcinoma.
Papatheofanis FJ
J Nucl Med; 1997 Aug; 38(8):1175-9. PubMed ID: 9255144
[TBL] [Abstract][Full Text] [Related]
20. Strontium-89 chloride for pain palliation in prostatic skeletal malignancy.
Laing AH; Ackery DM; Bayly RJ; Buchanan RB; Lewington VJ; McEwan AJ; Macleod PM; Zivanovic MA
Br J Radiol; 1991 Sep; 64(765):816-22. PubMed ID: 1717094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
